AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16939559 — intervention group
Group type: COMPARATOR
Intervention: No reduction in HbA1c
Number of subjects: 0
Study 14661000 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 6944 (small electrode surface area)
Number of subjects: 542
Study 14661000 — intervention group
Group type: COMPARATOR
Intervention: Model 6942 (conventional sized electrode surface area)
Number of subjects: 542
Study 10960626 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 398
Study 10960626 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/day
Number of subjects: 398
Study 10960626 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 398
Study 10960626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 1618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 12
Study 1618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12
Study 1618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 12
Study 1618254 — intervention group
Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 12
Study 6599665 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (n = 87)
Number of subjects: 496
Study 6599665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction intervention (n = 169)
Number of subjects: 496
Study 6599665 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 496
Study 6599665 — intervention group
Group type: COMPARATOR
Intervention: Control group (continue medication)
Number of subjects: 496
Study 30115584 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management and physical activity intervention including self-monitoring tools, a single exercise counseling home visit, and up to 11 telephone calls from a health coach over 20 weeks.
Number of subjects: 15
Study 30115584 — intervention group
Group type: COMPARATOR
Intervention: Self-directed control group received the same tools and materials but no home visit or coaching calls.
Number of subjects: 15
Study 30252192 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing protocol with home monitoring during a 12 week implementation
Number of subjects: 43
Study 30252192 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing protocol with home monitoring
Number of subjects: 43
Study 30252192 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing with home monitoring
Number of subjects: 43
Study 26295966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CPAP for 20 minutes via face mask
Number of subjects: 259
Study 26295966 — intervention group
Group type: COMPARATOR
Intervention: Standardized care without CPAP
Number of subjects: 259
Study 25454878 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL's TIV
Number of subjects: 1474
Study 22735103 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based early intervention delivered by specially trained community nurses (8 home visits)
Number of subjects: 667
Study 22735103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 667
Study 21090831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily for a median follow-up of 1.9 years
Number of subjects: 0
Study 21090831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 21090831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18062765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based exercise intervention
Number of subjects: 32
Study 18062765 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 32
Study 16055639 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prejudice expectations in a diary study of college roommates (Study 1)
Number of subjects: 0
Study 16055639 — intervention group
Group type: EXPERIMENTAL
Intervention: Situationally induced prejudice expectations in a laboratory interaction (Study 2)
Number of subjects: 0
Study 12014167 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence 10%
Number of subjects: 0
Study 12014167 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt 10%
Number of subjects: 0
Study 12014167 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent
Number of subjects: 0
Study 10575333 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg/day p.o. plus standard therapy
Number of subjects: 169
Study 10575333 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 169
Study 8720886 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 8720886 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 100
Study 1907675 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5% BCAA solution
Number of subjects: 80
Study 1907675 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% BCAA solution
Number of subjects: 80
Study 6125625 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-receptor blocker (10 mg of bunitrolol)
Number of subjects: 12
Study 6125625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31512148 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS (direct pulmonary pressure monitor system)
Number of subjects: 0
Study 31512148 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulmonary pressure-guided management
Number of subjects: 0
Study 31512148 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30744654 — intervention group
Group type: EXPERIMENTAL
Intervention: Maple Water (MW)
Number of subjects: 26
Study 30744654 — intervention group
Group type: COMPARATOR
Intervention: Control (maple-flavored bottled water)
Number of subjects: 26
Study 28379623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg once-daily aspirin
Number of subjects: 37
Study 28379623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg twice-daily aspirin
Number of subjects: 37
Study 28379623 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg once-daily aspirin
Number of subjects: 37
Study 28379623 — intervention group
Group type: COMPARATOR
Intervention: 100 mg once-daily aspirin (control group)
Number of subjects: 37
Study 28027636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education group sessions (12 weekly 75-min sessions)
Number of subjects: 238
Study 28027636 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflets on evidenced-based nutrition information)
Number of subjects: 238
Study 24408122 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan
Number of subjects: 1392
Study 24408122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study 23273217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months) consisting of neurorehabilitation treatment, empowerment training, and stroke education.
Number of subjects: 0
Study 23273217 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the nursing home and after discharge (Control group).
Number of subjects: 0
Study 23273217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months).
Number of subjects: 0
Study 21042404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 bite of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18
Study 21042404 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 bites of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18
Study 21042404 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 bites of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18
Study 21042404 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 3, or 5 bites)
Number of subjects: 18
Study 17923398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricutan
Number of subjects: 28
Study 17923398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15990659 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 336
Study 15990659 — intervention group
Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 336
Study 15990659 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat
Number of subjects: 336
Study 15990659 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation (EMS)
Number of subjects: 336
Study 15990659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe neck disability at baseline
Number of subjects: 336
Study 12483050 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncuffed, percutaneously inserted central venous catheters (CVCs)
Number of subjects: 1263
Study 12483050 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonized CVCs
Number of subjects: 1263
Study 12483050 — intervention group
Group type: EXPERIMENTAL
Intervention: CVCs causing BSIs
Number of subjects: 1263
Study 12483050 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncolonized CVCs
Number of subjects: 1263
Study 12483050 — intervention group
Group type: EXPERIMENTAL
Intervention: Local inflammation
Number of subjects: 1263
Study 9445119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 98
Study 9445119 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 98
Study 7623294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (150 micrograms kg‐1 orally)
Number of subjects: 8
Study 7623294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1777653 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 18
Study 1777653 — intervention group
Group type: COMPARATOR
Intervention: Control (no glipizide)
Number of subjects: 18
Study 6263442 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (lung cancer screening every four months for six years)
Number of subjects: 4500
Study 6263442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 4500
Study 31523022 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during surgery
Number of subjects: 120
Study 31523022 — intervention group
Group type: COMPARATOR
Intervention: Control group (without music during surgery)
Number of subjects: 120
Study 30972655 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive upper limb exercises and muscle relaxation training (PULE‐MRT) plus routine nursing care for 6 months
Number of subjects: 102
Study 30972655 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care for 6 months
Number of subjects: 102
Study 28396999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6045
Study 28396999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6045
Study 25666417 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg RGC
Number of subjects: 50
Study 25666417 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg RGC
Number of subjects: 50
Study 25666417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RGC-treated group
Number of subjects: 50
Study 25666417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23415472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 20 IU BID for 3 weeks
Number of subjects: 28
Study 23415472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23415472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (in a small group of inpatients)
Number of subjects: 28
Study 21235810 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGen LPS with navigation
Number of subjects: 90
Study 21235810 — intervention group
Group type: COMPARATOR
Intervention: NexGen LPS without navigation
Number of subjects: 90
Study 21235810 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Scorpio PS with navigation
Number of subjects: 90
Study 21235810 — intervention group
Group type: COMPARATOR
Intervention: Control group (NexGen LPS without navigation)
Number of subjects: 90
Study 21235810 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation (general)
Number of subjects: 90
Study 19808442 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVA‐1 group (circumferential pulmonary vein ablation with linear lesions along the LA roof)
Number of subjects: 120
Study 19808442 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVA‐2 group (circumferential pulmonary vein ablation with LA posterior wall isolation)
Number of subjects: 120
Study 19808442 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CPVA‐1 and CPVA‐2 groups
Number of subjects: 120
Study 17154160 — intervention group
Group type: EXPERIMENTAL
Intervention: Saforis (glutamine) powder, 3 times/day during Treatment Cycle 1
Number of subjects: 326
Study 17154160 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times/day during Treatment Cycle 1
Number of subjects: 326
Study 15466766 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg) plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Number of subjects: 72
Study 15466766 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Number of subjects: 72
Study 15466766 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg) plus Prednisone
Number of subjects: 72
Study 15466766 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Prednisone
Number of subjects: 72
Study 11244365 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (1 puff three times daily per nostril for 15 days)
Number of subjects: 89
Study 11244365 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 89
Study 9647686 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 9647686 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0
Study 9647686 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention conditions
Number of subjects: 0
Study 8018037 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 82
Study 8018037 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 82
Study 8018037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8018037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (Phenytoin and Carbamazepine)
Number of subjects: 82
Study 2644830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 91
Study 861375 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal radiotherapy with combination chemotherapy
Number of subjects: 52
Study 861375 — intervention group
Group type: COMPARATOR
Intervention: Total nodal radiotherapy without combination chemotherapy
Number of subjects: 52
Study 861375 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal radiotherapy
Number of subjects: 52
Study 31464082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 85
Study 31464082 — intervention group
Group type: COMPARATOR
Intervention: Coblation
Number of subjects: 85
Study 31464082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TORS and coblation
Number of subjects: 85
Study 27682442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored repositioning and a turning and repositioning system
Number of subjects: 0
Study 27682442 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized incontinence care
Number of subjects: 0
Study 27682442 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25796966 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavior Therapy for Insomnia (CBTI)
Number of subjects: 32
Study 25796966 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 32
Study 22889717 — intervention group
Group type: EXPERIMENTAL
Intervention: Real GSM-EMFs exposure (45 min)
Number of subjects: 10
Study 22889717 — intervention group
Group type: COMPARATOR
Intervention: Sham GSM-EMFs exposure (45 min)
Number of subjects: 10
Study 21511523 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual motion adaptation using a random dot kinematogram display
Number of subjects: 0
Study 21511523 — intervention group
Group type: COMPARATOR
Intervention: Baseline threshold TMS intensity
Number of subjects: 0
Study 19703236 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 60
Study 19703236 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with professional plaque control (PPC) (twice a week)
Number of subjects: 60
Study 19703236 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with chlorhexidine rinsing (CHX) (twice a day)
Number of subjects: 60
Study 17902187 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI) 25 mg every 14 days (60% of patients)
Number of subjects: 52
Study 17902187 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 52
Study 15499822 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of mortality
Number of subjects: 0
Study 15499822 — intervention group
Group type: COMPARATOR
Intervention: Control topic (aversive topic)
Number of subjects: 0
Study 15499822 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial instructions manipulating nullification proneness
Number of subjects: 0
Study 11595992 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine preparation of skin before and during catheterization
Number of subjects: 0
Study 11595992 — intervention group
Group type: COMPARATOR
Intervention: Scheduled replacement of catheters
Number of subjects: 0
Study 11595992 — intervention group
Group type: COMPARATOR
Intervention: Surveillance for nosocomial infections
Number of subjects: 0
Study 11595992 — intervention group
Group type: COMPARATOR
Intervention: Optimal method of aseptic insertion for central venous catheters
Number of subjects: 0
Study 11595992 — intervention group
Group type: COMPARATOR
Intervention: Impregnation of catheter and/or hub surfaces with antiseptics
Number of subjects: 0
Study 9010901 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive program (shortened lecture, clinical practice, small group feedback)
Number of subjects: 0
Study 9010901 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic teaching program
Number of subjects: 0
Study 7886282 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked order of trials
Number of subjects: 36
Study 7886282 — intervention group
Group type: COMPARATOR
Intervention: Serial order of trials
Number of subjects: 36
Study 2889528 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 10
Study 2889528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28488021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure training (CET + TAU), N = 40
Number of subjects: 58
Study 28488021 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU only), N = 18
Number of subjects: 58
Study 28488021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall subjects
Number of subjects: 58
Study 27241895 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400mcg
Number of subjects: 29
Study 27241895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 26233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (84 μg)
Number of subjects: 6
Study 26233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (84 μg)
Number of subjects: 6
Study 26233335 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS effects of dexmedetomidine
Number of subjects: 6
Study 26233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular effects of dexmedetomidine
Number of subjects: 6
Study 23483174 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care management of obstructive sleep apnea
Number of subjects: 155
Study 23483174 — intervention group
Group type: COMPARATOR
Intervention: Usual care in a specialist sleep center
Number of subjects: 155
Study 21120832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound Sense™ hearing conservation program
Number of subjects: 16
Study 18212347 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction (within 21 days)
Number of subjects: 69
Study 18212347 — intervention group
Group type: COMPARATOR
Intervention: Delayed reconstruction (beyond 6 weeks)
Number of subjects: 69
Study 16763748 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 mg soy isoflavones
Number of subjects: 90
Study 16763748 — intervention group
Group type: EXPERIMENTAL
Intervention: 126 mg soy isoflavones
Number of subjects: 90
Study 16763748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg soy isoflavones)
Number of subjects: 90
Study 16763748 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary total deoxypyridinoline
Number of subjects: 90
Study 14623802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 13
Study 14623802 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 13
Study 10890665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 34
Study 10890665 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive-pressure ventilation (IPPV)
Number of subjects: 34
Study 8717600 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Decision (SWD) scale
Number of subjects: 0
Study 1315211 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 plus radiation therapy (WR + RT)
Number of subjects: 100
Study 1315211 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) only
Number of subjects: 100
Study 3886724 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (10 mg three times a day)
Number of subjects: 50
Study 3886724 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (25 mg three times a day)
Number of subjects: 50